PrEP use remains largely limited to white men 25 and older, meaning groups at the very highest risk of HIV are likely not benefiting.

A recent analysis helped shed light on the stillborn rate among those living in wealthier nations.

Such generic drugs could save nations huge sums in the coming years.

But the median CD4 count at treatment start is below 350, which means work is needed to catch up to World Health Organization guidelines.

A five-state analysis found that the likelihood of such a conviction varied greatly based on race, sex and sexual orientation.

People who switched to a single-tablet regimen containing darunavir maintained viral suppression.

People with HIV taking Viread, especially if combined with Norvir, should receive regular kidney monitoring.

Following a recent finding of a major drop in HIV diagnoses at the 56 Dean St. clinic, the decline in gonorrhea diagnoses is encouraging.

Having taken Kaletra also raised the risk of erectile dysfunction in a recent study of this group.

In a national survey, men who have sex with men also cited anticipated difficulty accessing PrEP as a reason for not taking it.